Recent Investment Analysts’ Ratings Updates for United Therapeutics (UTHR)

Several analysts have recently updated their ratings and price targets for United Therapeutics (NASDAQ: UTHR):

• 8/20/2024 – United Therapeutics had its price target raised by analysts at Wells Fargo & Company from $350.00 to $380.00. They now have an “overweight” rating on the stock.
• 8/2/2024 – United Therapeutics was downgraded by analysts at StockNews.com from a “strong-buy” rating to a “buy” rating.
• 8/1/2024 – United Therapeutics had its price target lowered by analysts at Bank of America Co. from $303.00 to $280.00. They now have an “underperform” rating on the stock.
• 8/1/2024 – United Therapeutics was downgraded by analysts at LADENBURG THALM/SH SH from a “strong-buy” rating to a “hold” rating.
• 8/1/2024 – United Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $400.00 price target on the stock.
• 7/25/2024 – United Therapeutics had its price target raised by analysts at HC Wainwright from $300.00 to $400.00. They now have a “buy” rating on the stock.
• 7/15/2024 – United Therapeutics was upgraded by analysts at StockNews.com from a “buy” rating to a “strong-buy” rating.
• 7/11/2024 – United Therapeutics was downgraded by analysts at Morgan Stanley from an “overweight” rating to an “equal weight” rating. They now have a $321.00 price target on the stock, up previously from $310.00.
• 7/11/2024 – United Therapeutics had its price target raised by analysts at TD Cowen from $270.00 to $350.00. They now have a “buy” rating on the stock.
• 7/8/2024 – United Therapeutics had its price target raised by analysts at UBS Group AG from $300.00 to $370.00. They now have a “buy” rating on the stock.

United Therapeutics Stock Performance

NASDAQ UTHR traded down $4.64 on Thursday, reaching $346.97. The stock had a trading volume of 248,954 shares, compared to its average volume of 498,187. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.35 and a quick ratio of 4.18. The firm has a fifty day moving average of $321.69 and a two-hundred day moving average of $271.04. United Therapeutics Co. has a 1-year low of $208.62 and a 1-year high of $353.49. The company has a market cap of $15.44 billion, a P/E ratio of 16.41, a price-to-earnings-growth ratio of 1.16 and a beta of 0.55.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $6.33 by ($0.48). United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The company had revenue of $714.90 million for the quarter, compared to the consensus estimate of $691.87 million. During the same quarter last year, the business earned $5.24 earnings per share. United Therapeutics’s revenue was up 19.8% compared to the same quarter last year. On average, equities research analysts anticipate that United Therapeutics Co. will post 24.79 EPS for the current year.

Insider Buying and Selling

In related news, Director Christopher Causey sold 2,000 shares of United Therapeutics stock in a transaction on Thursday, June 13th. The stock was sold at an average price of $281.53, for a total transaction of $563,060.00. Following the sale, the director now directly owns 4,185 shares in the company, valued at $1,178,203.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $344.18, for a total transaction of $1,239,048.00. Following the completion of the transaction, the chief executive officer now directly owns 130 shares in the company, valued at $44,743.40. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Christopher Causey sold 2,000 shares of the business’s stock in a transaction dated Thursday, June 13th. The shares were sold at an average price of $281.53, for a total value of $563,060.00. Following the completion of the sale, the director now directly owns 4,185 shares of the company’s stock, valued at approximately $1,178,203.05. The disclosure for this sale can be found here. Over the last three months, insiders have sold 122,266 shares of company stock worth $38,604,580. 12.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. SG Americas Securities LLC increased its position in United Therapeutics by 176.2% during the 1st quarter. SG Americas Securities LLC now owns 14,315 shares of the biotechnology company’s stock valued at $3,288,000 after buying an additional 9,133 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in shares of United Therapeutics by 19.0% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 25,686 shares of the biotechnology company’s stock valued at $5,901,000 after acquiring an additional 4,100 shares in the last quarter. International Assets Investment Management LLC lifted its position in shares of United Therapeutics by 13,769.2% in the fourth quarter. International Assets Investment Management LLC now owns 9,015 shares of the biotechnology company’s stock valued at $1,982,000 after acquiring an additional 8,950 shares in the last quarter. BNP Paribas Financial Markets lifted its position in shares of United Therapeutics by 90.3% in the fourth quarter. BNP Paribas Financial Markets now owns 55,481 shares of the biotechnology company’s stock valued at $12,200,000 after acquiring an additional 26,325 shares in the last quarter. Finally, Comerica Bank increased its holdings in shares of United Therapeutics by 5.9% in the first quarter. Comerica Bank now owns 165,911 shares of the biotechnology company’s stock worth $38,113,000 after purchasing an additional 9,244 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.